Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.

Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, Guigay J, Cupissol D, Delord JP, Lallemant B, Alfonsi M, Aubry K, Mazel M, Becher F, Perriard F, Chatelut E, Thomas F.

Br J Clin Pharmacol. 2019 Jun;85(6):1357-1366. doi: 10.1111/bcp.13907. Epub 2019 Apr 13.

PMID:
30811063
2.

Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.

Vergez S, Delord JP, Thomas F, Rochaix P, Caselles O, Filleron T, Brillouet S, Canal P, Courbon F, Allal BC.

Clin Cancer Res. 2010 Sep 1;16(17):4434-45. doi: 10.1158/1078-0432.CCR-09-2795. Epub 2010 Jul 26.

3.

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.

Delord JP, Quideau S, Rochaix P, Caselles O, Couderc B, Hennebelle I, Courbon F, Canal P, Allal BC.

Br J Cancer. 2010 Jun 29;103(1):61-72. doi: 10.1038/sj.bjc.6605699. Epub 2010 Jun 1.

4.

Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.

Dalenc F, Doisneau-Sixou SF, Allal BC, Marsili S, Lauwers-Cances V, Chaoui K, Schiltz O, Monsarrat B, Filleron T, Renée N, Malissein E, Meunier E, Favre G, Roché H.

Clin Cancer Res. 2010 Feb 15;16(4):1264-71. doi: 10.1158/1078-0432.CCR-09-1192. Epub 2010 Feb 9.

5.

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.

Balin-Gauthier D, Delord JP, Pillaire MJ, Rochaix P, Hoffman JS, Bugat R, Cazaux C, Canal P, Allal BC.

Br J Cancer. 2008 Jan 15;98(1):120-8. doi: 10.1038/sj.bjc.6604134. Epub 2008 Jan 8.

6.

Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.

Thomas F, Rochaix P, Benlyazid A, Sarini J, Rives M, Lefebvre JL, Allal BC, Courbon F, Chatelut E, Delord JP.

Clin Cancer Res. 2007 Dec 1;13(23):7086-92.

Supplemental Content

Loading ...
Support Center